About Aucliciclib (LS010, QHRD110)

AUCLICICLIB is a selective and potent CDK4/6 inhibitor with pico-molar potency when profiled against 371 human kinases, which indicates that it is markedly more selective than any CDK inhibitors identified to date. Oral administration of AUCLICICLIB was shown to inhibit tumour growth in several xenograft in vivo models, including ovarian cancer, colorectal cancer and GBM. Preclinical data demonstrates that AUCLICICLIB is capable of crossing the BBB of the mouse brain and does so more readily than the FDA-approved CDK4/6 inhibitors, suggesting that AUCLICICLIB is an ideal drug candidate for treating primary brain tumours and central nervous system metastatic disease.

LeSun Pharma provided preparation R&D services for AUCLICICLIB. In order to ensure the quality of R&D, LeSun Pharma helped to accelerate the R&D process through rigorous trial design, meticulous project management and efficient communication. Noteblely, AUCLICICLIB got approval within 4 months. In the future, AUCLICICLIB will open a new stage for the treatment of advanced tumor.

The AUCLICICLIB study is registered on Chinadrugtrials.org (Registration no.: CTR20233705). 

About LeSun Pharma

LeSun Pharma is a pharmaceutical company focusing on the research and development of innovative drugs for cycle dependent kinase. It was founded by well-known Professor Shudong Wang, is the Head of Drug Discovery and Development pharmaceutical center, University of South Australia. The management team has extensive experience in drug synthesis, pharmaceutical evaluation and project management. The company strives to utilize the most advanced life science technologies to obtain new medicine with high efficiency and low side effect, and eventually to alleviate the pain of patients and save the lives of patients.

About Qianhong Bio-pharma

Changzhou Qianhong Biopharma Co.,Ltd. is a leading manufacturer and distributor of polysaccharide and protease drugs in the domestic biochemical pharmaceutical industry, a national high-tech enterprise and a key backbone enterprise of the national three-drug base, and has won the title of national and provincial and municipal drug quality integrity demonstration enterprise for many years. On February 18, 2011, it was successfully listed on the Shenzhen Stock Exchange. At present, it has four holding subsidiaries: ZonHon Biopharma Institute, Inc. (hereinafter referred to as ZonhonBio), Le Sun Pharmaceuticals Ltd. (hereinafter referred to as Le Sun), Qianhong Healthcare Co., Ltd. (hereinafter referred to as Qianhong Healthcare) and Hubei Runhong Biological Technology Co., Ltd. (hereinafter referred to as Hubei Runhong).